Cargando…
Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches
Ischemic heart failure (IHF) is a leading cause of morbidity and mortality worldwide, for which heart transplantation remains the only definitive treatment. IHF manifests from myocardial infarction (MI) that initiates tissue remodeling processes, mediated by mechanical changes in the tissue (loss of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913034/ https://www.ncbi.nlm.nih.gov/pubmed/36763330 http://dx.doi.org/10.1007/s13346-023-01290-2 |
_version_ | 1784885330337333248 |
---|---|
author | Soni, Shreya S. D’Elia, Arielle M. Rodell, Christopher B. |
author_facet | Soni, Shreya S. D’Elia, Arielle M. Rodell, Christopher B. |
author_sort | Soni, Shreya S. |
collection | PubMed |
description | Ischemic heart failure (IHF) is a leading cause of morbidity and mortality worldwide, for which heart transplantation remains the only definitive treatment. IHF manifests from myocardial infarction (MI) that initiates tissue remodeling processes, mediated by mechanical changes in the tissue (loss of contractility, softening of the myocardium) that are interdependent with cellular mechanisms (cardiomyocyte death, inflammatory response). The early remodeling phase is characterized by robust inflammation that is necessary for tissue debridement and the initiation of repair processes. While later transition toward an immunoregenerative function is desirable, functional reorientation from an inflammatory to reparatory environment is often lacking, trapping the heart in a chronically inflamed state that perpetuates cardiomyocyte death, ventricular dilatation, excess fibrosis, and progressive IHF. Therapies can redirect the immune microenvironment, including biotherapeutic and biomaterial-based approaches. In this review, we outline these existing approaches, with a particular focus on the immunomodulatory effects of therapeutics (small molecule drugs, biomolecules, and cell or cell-derived products). Cardioprotective strategies, often focusing on immunosuppression, have shown promise in pre-clinical and clinical trials. However, immunoregenerative therapies are emerging that often benefit from exacerbating early inflammation. Biomaterials can be used to enhance these therapies as a result of their intrinsic immunomodulatory properties, parallel mechanisms of action (e.g., mechanical restraint), or by enabling cell or tissue-targeted delivery. We further discuss translatability and the continued progress of technologies and procedures that contribute to the bench-to-bedside development of these critically needed treatments. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9913034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-99130342023-02-13 Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches Soni, Shreya S. D’Elia, Arielle M. Rodell, Christopher B. Drug Deliv Transl Res Original Article Ischemic heart failure (IHF) is a leading cause of morbidity and mortality worldwide, for which heart transplantation remains the only definitive treatment. IHF manifests from myocardial infarction (MI) that initiates tissue remodeling processes, mediated by mechanical changes in the tissue (loss of contractility, softening of the myocardium) that are interdependent with cellular mechanisms (cardiomyocyte death, inflammatory response). The early remodeling phase is characterized by robust inflammation that is necessary for tissue debridement and the initiation of repair processes. While later transition toward an immunoregenerative function is desirable, functional reorientation from an inflammatory to reparatory environment is often lacking, trapping the heart in a chronically inflamed state that perpetuates cardiomyocyte death, ventricular dilatation, excess fibrosis, and progressive IHF. Therapies can redirect the immune microenvironment, including biotherapeutic and biomaterial-based approaches. In this review, we outline these existing approaches, with a particular focus on the immunomodulatory effects of therapeutics (small molecule drugs, biomolecules, and cell or cell-derived products). Cardioprotective strategies, often focusing on immunosuppression, have shown promise in pre-clinical and clinical trials. However, immunoregenerative therapies are emerging that often benefit from exacerbating early inflammation. Biomaterials can be used to enhance these therapies as a result of their intrinsic immunomodulatory properties, parallel mechanisms of action (e.g., mechanical restraint), or by enabling cell or tissue-targeted delivery. We further discuss translatability and the continued progress of technologies and procedures that contribute to the bench-to-bedside development of these critically needed treatments. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-02-10 2023 /pmc/articles/PMC9913034/ /pubmed/36763330 http://dx.doi.org/10.1007/s13346-023-01290-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Soni, Shreya S. D’Elia, Arielle M. Rodell, Christopher B. Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
title | Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
title_full | Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
title_fullStr | Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
title_full_unstemmed | Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
title_short | Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
title_sort | control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913034/ https://www.ncbi.nlm.nih.gov/pubmed/36763330 http://dx.doi.org/10.1007/s13346-023-01290-2 |
work_keys_str_mv | AT sonishreyas controlofthepostinfarctimmunemicroenvironmentthroughbiotherapeuticandbiomaterialbasedapproaches AT deliaariellem controlofthepostinfarctimmunemicroenvironmentthroughbiotherapeuticandbiomaterialbasedapproaches AT rodellchristopherb controlofthepostinfarctimmunemicroenvironmentthroughbiotherapeuticandbiomaterialbasedapproaches |